Guerbet: decline in half-year EBITDA margin
The specialist in contrast products and solutions for medical imaging reported sales of 378.6 million euros, up 2% on a reported basis and 2.8% at constant exchange rates (excluding currency impact).
Guerbet maintains its 2023 objectives of sales growth in excess of 5% on a like-for-like basis and at constant exchange rates, and an adjusted EBITDA margin of around 11%, before returning in 2024 to a level higher than that achieved in 2021 (14.4%).
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction